Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma

被引:69
作者
Bonner, James A. [1 ]
Trummell, Hoa Q. [1 ]
Willey, Christopher D. [1 ]
Plants, Brian A. [1 ]
Raisch, Kevin P. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35233 USA
关键词
STAT-3; Radiosensitization; EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR; SIGNAL TRANSDUCER; CONSTITUTIVE ACTIVATION; APOPTOSIS; CANCER; HEAD; TRANSCRIPTION-3; RADIOTHERAPY; C225;
D O I
10.1016/j.radonc.2009.06.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Signal transducer and activator of transcription-3 (STAT-3) is a downstream component of the Epidermal Growth Factor Receptor (EGFr) signaling process that may facilitate the resistance of tumor cells to conventional cancer treatments. Studies were performed to determine if inhibition of this downstream protein produces radiosensitization. Methods/Results: A431 cells (human squamous cell carcinoma cells with EGFr overexpression) were found to be sensitized to radiation after treatment with STAT-3 small interfering RNA (siRNA). Therefore. a short hairpin RNA (shRNA) against STAT-3 was designed and cloned into a pBABE vector system modified for shRNA expression. Following transfection, clone 2.1 was selected for further study as it showed a dramatic reduction of STAT-3 protein (and mRNA) when compared to A431 parental cells or a negative control shRNA cell line (transfected with STAT-3 shRNA with 2 base pairs mutated). A431 2.1 showed doubling times of 25-31 h as compared to 18-24 h for the parental cell line. The A431 shRNA knockdown STAT-3 cells A431 were more sensitive to radiation than A431 parental or negative STAT-3 control cells. Conclusion: A431 cells stably transfected with shRNA against STAT-3 resulted in enhanced radiosensitivity. Further work will be necessary to determine whether the inhibition of STAT-3 phosphorylation is a necessary step for the radiosensitization that is induced by the inhibition of EGFr. (C) 2009 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 92 (2009) 339-344
引用
收藏
页码:339 / 344
页数:6
相关论文
共 26 条
[1]   Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma [J].
Aoki, Y ;
Feldman, GM ;
Tosato, G .
BLOOD, 2003, 101 (04) :1535-1542
[2]   Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-XL enhances antitumor effects in squamous cell carcinoma of the head and neck [J].
Boehm, Amanda L. ;
Sen, Malabika ;
Seethala, Raja ;
Gooding, William E. ;
Freilino, Maria ;
Wong, Silvia Man Yan ;
Wang, Shaomeng ;
Johnson, Daniel E. ;
Grandis, Jennifer Rubin .
MOLECULAR PHARMACOLOGY, 2008, 73 (06) :1632-1642
[3]   Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression [J].
Bonner, JA ;
Buchsbaum, DJ ;
Russo, SM ;
Fiveash, JB ;
Trummell, HQ ;
Curiel, DT ;
Raisch, KP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (02) :2-10
[4]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[5]   THE INTERACTION OF EPIDERMAL GROWTH-FACTOR AND RADIATION IN HUMAN HEAD AND NECK SQUAMOUS-CELL CARCINOMA CELL-LINES WITH VASTLY DIFFERENT RADIOSENSITIVITIES [J].
BONNER, JA ;
MAIHLE, NJ ;
FOLVEN, BR ;
CHRISTIANSON, TJH ;
SPAIN, K .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (02) :243-247
[6]  
Bonner JA, 2000, J CLIN ONCOL, V18, p47S
[7]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[8]  
COLTON T, 1974, STAT MED, P131
[9]   Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study [J].
Dobelbower, MC ;
Russo, SM ;
Raisch, KP ;
Seay, LL ;
Clemons, LK ;
Suter, S ;
Posey, J ;
Bonner, JA .
ANTI-CANCER DRUGS, 2006, 17 (01) :95-102
[10]   MEAN INACTIVATION DOSE - A USEFUL CONCEPT FOR INTERCOMPARISON OF HUMAN CELL-SURVIVAL CURVES [J].
FERTIL, B ;
DERTINGER, H ;
COURDI, A ;
MALAISE, EP .
RADIATION RESEARCH, 1984, 99 (01) :73-84